Mesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion

Nephrology Dialysis Transplantation

Volumn 29, Issue 8, 2014, Pages 1487-1493

  Erpicum, Pauline ^a   Detry, Olivier ^a,b   Weekers, Laurent ^a   Bonvoisin, Catherine ^a   Lechanteur, Chantal ^a   Briquet, Alexandra ^a,b   Beguin, Yves ^a,b   Krzesinski, Jean Marie ^a,b   Jouret, François ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

acute kidney injury; ischaemia reperfusion; ischaemic conditioning; kidney transplantation; mesenchymal stromal cells

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR7; COLLAGEN TYPE 1; MESSENGER RNA; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; STROMAL CELL DERIVED FACTOR 1; THYMOCYTE ANTIBODY; VIMENTIN;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ANTIINFLAMMATORY ACTIVITY; CELL DIFFERENTIATION; CELL LINEAGE; CELL MIGRATION; CELL POPULATION; CHRONIC ALLOGRAFT NEPHROPATHY; DISEASE SEVERITY; GRAFT SURVIVAL; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; ISCHEMIC PRECONDITIONING; KIDNEY GRAFT REJECTION; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MESODERM; MULTIPOTENT STEM CELL; NONHUMAN; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL GRAFT DYSFUNCTION; REPERFUSION; REPERFUSION INJURY; REVIEW; TISSUE REGENERATION; TISSUE REPAIR;

ACUTE KIDNEY INJURY; ISCHAEMIA/REPERFUSION; ISCHAEMIC CONDITIONING; KIDNEY TRANSPLANTATION; MESENCHYMAL STROMAL CELLS;

ADULT; ANIMALS; HUMANS; KIDNEY; KIDNEY DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; REPERFUSION INJURY;

EID: 84905010318     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft538     Document Type: Review

References (49)

1. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl.2 2012; 19-36
2. Schrier RW, Wang W, Poole B et al. Acute renal failure: Definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004; 114: 5-14
3. Bouma HR, Ploeg RJ, Schuurs TA. Signal transduction pathways involved in brain death-induced renal injury. Am J Transplant 2009; 9: 989-997
4. Thakar CV. Perioperative acute kidney injury. Adv Chronic Kidney Dis 2013; 20: 67-75
5. Caplan AI. Mesenchymal stem cells. J Orthop Res 1991; 9: 641-650
6. Kern S, Eichler H, Stoeve J et al. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006; 24: 1294-1301
7. Li XC, Turka LA. An update on regulatory T cells in transplant tolerance and rejection. Nat Rev Nephrol 2010; 6: 577-583
8. Selmani Z, Naji A, Zidi I et al. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212-222
9. Mokarizadeh A, Delirezh N, Morshedi A et al. Microvesicles derived from mesenchymal stem cells: Potent organelles for induction of tolerogenic signaling. Immunol Lett. 2012; 147: 47-54
10. Bruno S, Grange C, Collino F et al. Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury. PLoS One 2012; 7: E33115
11. Islam MN, Das SR, Emin MT et al. Mitochondrial transfer from bonemarrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med 2012; 18: 759-765
12. Carrion F, Nova E, Luz P et al. Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. Immunol Lett 2011; 135: 10-16
13. Kim J, Hematti P. Mesenchymal stem cell-educated macrophages: A novel type of alternatively activated macrophages. Exp Hematol 2009; 37: 1445-1453
14. Maggini J, Mirkin G, Bognanni I et al. Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile. PLoS One 2010; 5: E9252
15. Zhao ZG, Xu W, Sun L et al. Immunomodulatory function of regulatory dendritic cells induced by mesenchymal stem cells. Immunol Invest 2012; 41: 183-198
16. Souidi N, Stolk M, Seifert M. Ischemia-reperfusion injury: Beneficial effects of mesenchymal stromal cells. Curr Opin Organ Transplant 2013; 18: 34-43
17. Togel FE, Westenfelder C. Mesenchymal stem cells: A new therapeutic tool for AKI. Nat Rev Nephrol 2010; 6: 179-183
18. Seo-Mayer PW, Thulin G, Zhang L et al. Preactivation of AMPK by metformin may ameliorate the epithelial cell damage caused by renal ischemia. Am J Physiol Renal Physiol 2011; 301: F1346-F1357
19. Li C, Jackson RM. Reactive species mechanisms of cellular hypoxia-reoxygenation injury. Am J Physiol Cell Physiol 2002; 282: C227-C241
20. Bon D, Chatauret N, Giraud S et al. New strategies to optimize kidney recovery and preservation in transplantation. Nat Rev Nephrol 2012; 8: 339-347
21. Ioannou A, Dalle Lucca J, Tsokos GC. Immunopathogenesis of ischemia/ reperfusion-Associated tissue damage. Clin Immunol 2011; 141: 3-14
22. Fuquay R, Renner B, Kulik L et al. Renal ischemia-reperfusion injury amplifies the humoral immune response. J Am Soc Nephrol 2013; 24: 1063-1072
23. Renner B, Strassheim D, Amura CR et al. B cell subsets contribute to renal injury and renal protection after ischemia/reperfusion. J Immunol 2010; 185: 4393-4400
24. Jang HR, Gandolfo MT, Ko GJ et al. B cells limit repair after ischemic acute kidney injury. J Am Soc Nephrol 2010; 21: 654-665
25. Eltzschig HK, Eckle T. Ischemia and reperfusion-from mechanism to translation. Nat Med 2011; 17: 1391-1401
26. Bonventre JV. Kidney ischemic preconditioning. Curr Opin Nephrol Hypertens 2002; 11: 43-48
27. Bouma HR, Carey HV, Kroese FG. Hibernation: The immune system at rest? J Leukoc Biol 2010; 88: 619-624
28. Wever KE, Menting TP, Rovers M et al. Ischemic preconditioning in the animal kidney, a systematic review and meta-Analysis. PLoS One 2012; 7: E32296
29. Wever KE, Masereeuw R, Wagener FA et al. Humoral signalling compounds in remote ischaemic preconditioning of the kidney, a role for the opioid receptor. Nephrol Dial Transplant 2013; 28: 1721-1732
30. Togel F, Hu Z, Weiss K et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289: F31-F42
31. Liu H, Liu S, Li Y et al. The role of SDF-1-CXCR4/CXCR7 axis in the therapeutic effects of hypoxia-preconditioned mesenchymal stem cells for renal ischemia/reperfusion injury. PLoS One 2012; 7: E34608
32. Eggenhofer E, Benseler V, Kroemer A et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012; 3: 297
33. Cao H, Qian H, Xu Wet al. Mesenchymal stem cells derived from human umbilical cord ameliorate ischemia/reperfusion-induced acute renal failure in rats. Biotechnol Lett 2010; 32: 725-732
34. Chen YT, Sun CK, Lin YC et al. Adipose-derived mesenchymal stem cell protects kidneys against ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction. J Transl Med 2011; 9: 51
35. Donizetti-Oliveira C, Semedo P, Burgos-Silva M et al. Adipose tissuederived stem cell treatment prevents renal disease progression. Cell Transplant 2012; 21: 1727-1741
36. Altun B, Yilmaz R, Aki T et al. Use of mesenchymal stem cells and darbepoetin improve ischemia-induced acute kidney injury outcomes. Am J Nephrol 2012; 35: 531-539
37. Xinaris C, Morigi M, Benedetti V et al. A novel strategy to enhance mesenchymal stem cell migration capacity and promote tissue repair in an injury specific fashion. Cell Transplant 2013; 22: 423-436
38. Gatti S, Bruno S, DeregibusMC et al.Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 2011; 26: 1474-1483
39. Bruno S, Grange C, Deregibus MC et al. Mesenchymal stem cell-derived microvesicles protect against acute tubular injury. J Am Soc Nephrol 2009; 20: 1053-1067
40. Heemann U, Lutz J. Pathophysiology and treatment options of chronic renal allograft damage. Nephrol Dial Transplant 2013; 28: 2438-2446
41. Casiraghi F, Perico N, Remuzzi G. Mesenchymal stromal cells to promote solid organ transplantation tolerance. Curr Opin Organ Transplant 2013; 18: 51-58
42. Roemeling-van Rhijn M, Reinders ME, de Klein A et al. Mesenchymal stem cells derived from adipose tissue are not affected by renal disease. Kidney Int 2012; 82: 748-758
43. Hara Y, Stolk M, Ringe J et al. In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemia. Transpl Int 2011; 24: 1112-1123
44. Seifert M, Stolk M, Polenz D et al. Detrimental effects of rat mesenchymal stromal cell pre-Treatment in a model of acute kidney rejection. Front Immunol 2012; 3: 202
45. Casiraghi F, Azzollini N, Todeschini M et al. Localization of mesenchymal stromal cells dictates their immune or proinflammatory effects in kidney transplantation. Am J Transplant 2012; 12: 2373-2383
46. Franquesa M, Herrero E, Torras J et al. Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model. Stem Cells Dev 2012; 21: 3125-3135
47. Franquesa M, Hoogduijn MJ, Reinders ME et al. Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: Lessons learned from first clinical trials. Transplantation 2013; 96: 234-238
48. Perico N, Casiraghi F, Introna M et al. Autologous mesenchymal stromal cells and kidney transplantation: A pilot study of safety and clinical feasibility. Clin J Am Soc Nephrol 2011; 6: 412-422
49. Perico N, Casiraghi F, Gotti E et al. Mesenchymal stromal cells and kidney transplantation: Pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transpl Int 2013; 26: 867-878